Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.78B |
| 2 |
Microsoft
MSFT
|
+$2.22B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.67B |
| 4 |
Invesco QQQ Trust
QQQ
|
+$1.65B |
| 5 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$1.19B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.45B |
| 2 |
iShares US Real Estate ETF
IYR
|
+$533M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$410M |
| 4 |
Stellantis
STLA
|
+$312M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$240M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.28% |
| 2 | Healthcare | 11.27% |
| 3 | Financials | 10.52% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 7.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KALV
3726
DELISTED
KalVista Pharmaceuticals
KALV
| $44.2K | ﹤0.01% |
4,906
-7,507
| -60% | -$69.2K |
|
|
KNTE
3727
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $44.1K | ﹤0.01% |
14,568
-14,857
| -50% | -$57.3K |
|
|
SCU
3728
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $44K | ﹤0.01% |
4,979
-7,608
| -60% | -$66.1K |
|
3729
Suburban Propane Partners
SPH
$1.24B
| $43.9K | ﹤0.01% |
2,968
-265
| -8% | -$4.01K |
|
|
AKTS
3730
DELISTED
Akoustis Technologies Inc
AKTS
| $43.7K | ﹤0.01% |
13,757
-19,845
| -59% | -$60.9K |
|
3731
GSK
GSK
$104B
| $43.7K | ﹤0.01% |
1,226
-83,180
| -99% | -$2.98M |
|
3732
Red Robin
RRGB
$145M
| $43.7K | ﹤0.01% |
3,158
-42,351
| -93% | -$568K |
|
3733
Norwood Financial Corp
NWFL
$370M
| $43.6K | ﹤0.01% |
1,476
+565
| +62% | +$15.5K |
|
3734
iShares MSCI EAFE Value ETF
EFV
$28.8B
| $43.6K | ﹤0.01% |
890
| – | – |
|
3735
Immunovant
IMVT
$7.93B
| $43.4K | ﹤0.01% |
2,286
+2,200
| +2,558% | +$41K |
|
3736
iShares Asia 50 ETF
AIA
$4.6B
| $43.2K | ﹤0.01% |
725
| – | – |
|
3737
Holley
HLLY
$321M
| $43K | ﹤0.01% |
10,514
-15,602
| -60% | -$46.5K |
|
3738
Harvard Bioscience
HBIO
$27.5M
| $43K | ﹤0.01% |
+783
| New | +$43K |
|
3739
Pure Cycle
PCYO
$253M
| $42.9K | ﹤0.01% |
3,899
-5,985
| -61% | -$59.4K |
|
3740
Douglas Elliman
DOUG
$154M
| $42.7K | ﹤0.01% |
19,254
-21,778
| -53% | -$59.8K |
|
3741
Sasol
SSL
$7.5B
| $42.6K | ﹤0.01% |
3,442
-594
| -15% | -$7.65K |
|
|
ENTF
3742
DELISTED
Enterprise 4.0 Technology Acquisition Corp. Class A Ordinary Shares
ENTF
| $42.6K | ﹤0.01% |
4,000
-496,000
| -99% | -$5.23M |
|
|
DBTX
3743
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $41.8K | ﹤0.01% |
10,855
| – | – |
|
3744
Greene County Bancorp
GCBC
$570M
| $41.4K | ﹤0.01% |
1,389
-2,033
| -59% | -$49K |
|
3745
Inhibikase Therapeutics
IKT
$342M
| $41.4K | ﹤0.01% |
+11,455
| New | +$42.7K |
|
3746
Assembly Biosciences
ASMB
$498M
| $41.3K | ﹤0.01% |
2,994
| – | – |
|
|
MCHB
3747
Mechanics Bancorp
MCHB
$3.72B
| $41.1K | ﹤0.01% |
6,949
-20,887
| -75% | -$196K |
|
3748
iShares S&P Small-Cap 600 Value ETF
IJS
$8.12B
| $40.9K | ﹤0.01% |
430
| – | – |
|
3749
Ring Energy
REI
$315M
| $40.9K | ﹤0.01% |
23,903
-23,660
| -50% | -$43.4K |
|
|
GPGI
3750
GPGI Inc
GPGI
$3.83B
| $40.8K | ﹤0.01% |
7,153
-6,862
| -49% | -$41.1K |
|
Similar funds
Barclays's Q2 2023 Portfolio in Review
As of Q2 2023, Barclays held 5,371 positions worth $158B, down 28% from $218B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Barclays withdrew a net $70.1B in Q2 2023, closing 872 positions and reducing 1,669 holdings. Its most notable exit was DCP Midstream, LP, an estimated $47.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 12% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Barclays opened a new position in State Street SPDR Nuveen ICE Municipal Bond ETF worth $36.9M.
- Barclays's largest Q2 2023 buy was State Street SPDR Nuveen ICE Municipal Bond ETF: 799,988 shares worth $36.9M.
- Barclays added most to Apple in Q2 2023, an estimated $2.78B increase.
- Barclays's biggest Q2 2023 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.45B.
- Barclays fully exited DCP Midstream, LP in Q2 2023, selling an estimated $47.3M.
- Barclays's ten largest holdings make up 24% of its $158B portfolio in Q2 2023.
- Barclays opened 314 new positions and closed 872 in Q2 2023.
- Barclays's portfolio value fell 28% quarter-over-quarter to $158B.
Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.